Has Gilbert Bader, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,178 in general payments to Gilbert Bader, MD across 118 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Gilbert Bader, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Gilbert Bader, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Gilbert Bader, MD

Medical Oncology · Columbus, OHNPI 1568800738

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,909 of the $2,178 with a category attached, or 87.6%. It is spread thinly across 30 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,741 and has fallen 92.5% since, to $131 in 2025. That places this record below the midpoint for medical oncology clinicians in OH, where the typical reported total is $2,659.

$2,178in general payments, 2019–2025

Across 118 payments — averaging $18.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Genentech USA, Inc.$342
Amgen$339
Merck$240
E.r. Squibb & Sons, L.L.C.$150
Novartis$131
Incyte Corporation$124
plus $853 from 24 others

$9,172in research payments, 2019–2025

Across 4 payments — averaging $2292.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Tolmar, Inc.$9K

What the payments were for

Speaking & faculty fees$753%
Food & beverage$1,90988%
Education$1949%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Genentech USA, Inc.	11	$342
Amgen	16	$339
Merck	12	$240
E.r. Squibb & Sons, L.L.C.	13	$150
Novartis	1	$131
Incyte Corporation	19	$124
Bristol Myers Squibb	6	$119
AstraZeneca(2 entities)	2	$94
Sanofi	4	$90
Eisai Inc.	1	$83
Lilly USA, LLC	4	$58
Pfizer	4	$50
Ipsen Biopharmaceuticals, Inc	3	$47
Boehringer Ingelheim	2	$32
Seagen Inc.	2	$28
AbbVie	2	$27
Takeda Pharmaceuticals U.S.A., Inc.	2	$23
Puma Biotechnology, Inc.	2	$23
Astellas Pharma US Inc	1	$21
EUSA Pharma (US) LLC	1	$20
Pharmacyclics LLC, An Abbvie Company	1	$17
Blueprint Medicines Corporation	1	$16
CSL Behring	1	$16
Jazz Pharmaceuticals Inc.	1	$15
Daiichi Sankyo Inc.	1	$14
Regeneron Healthcare Solutions, Inc.	1	$13
GSK	1	$12
Bayer	1	$12
Exelixis Inc.	1	$12
Servier Pharmaceuticals LLC	1	$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

KISQALI$131
KEYTRUDA$115

How this compares

$2,178 in reported general payments places this provider in the 45th percentile of 157 medical oncology providers in Ohio.

See all medical oncology providers in Ohio →

Medicare billing

Part B allowed, 2024

$31,545

Medicare patients

129

Services billed

289

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Anastrozole	184	$2,860
Ondansetron Hcl	21	$1,718
Letrozole	33	$808
Tamoxifen Citrate	34	$422
LoperamideLoperamide Hcl	13	$199
Prochlorperazine Maleate	14	$141

Paid to pharmacies, not to this prescriber.

Other medical oncology in Columbus

David CarboneColumbus$438K
Christian RolfoColumbus$227K
Timothy MooreColumbus$213K
Maryam LustbergColumbus$176K
Timothy BurnsColumbus$64K
Kai HeColumbus$49K
Gregory OttersonColumbus$49K
Sagar SardesaiColumbus$45K
Asrar AlahmadiColumbus$36K
John HaysColumbus$35K

See the full list for Ohio →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →